Postdoktor inom mRNA-baserad CAR T-cellsterapi
Karolinska Institutet · Flemingsberg, Sweden
Marcus Buggert’s group at the Centre for Infectious Medicine develops mRNA-based, CD19-directed CAR T cells for chronic lymphocytic leukaemia. The project uses electroporation and targeted lipid nanoparticles to generate transient CAR expression and examines how disease stage, treatment and T-cell differentiation affect killing of malignant B cells. Work combines primary human cells and patient samples, functional co-cultures, high-parameter flow cytometry and live-cell imaging to study killing kinetics, serial killing and repeated mRNA delivery. Phenotypic, transcriptional and epigenetic analyses will identify mechanisms limiting cytotoxicity and routes to improve receptor availability and function. This full-time postdoctoral appointment is based in Flemingsberg; applications through Varbi close on 6 October 2026.